Indian drug maker Alembic Pharmaceuticals has reported a strong financial performance for the fourth quarter of FY26, driven by steady growth in domestic formulations, robust US business expansion, and its strategic entry into the branded pharmaceuticals segment in the United States.
According to the company’s audited financial results released on May 15, 2026, consolidated revenue from operations increased 4% year-on-year to Rs 1,848 crore during Q4 FY26, while Profit After Tax (PAT) surged 29% to Rs 203 crore.
The company’s EBITDA before R&D expenditure rose 8% year-on-year to Rs 455 crore, with pre-R&D EBITDA margin standing at 25%.
Managing Director Pranav Amin said the quarter reflected disciplined execution across business segments and continued focus on profitability and long-term growth investments. He also highlighted the company’s entry into the US branded pharmaceutical business through the launch of Pivya®.
A major highlight of the quarter was the commercial launch of Pivya® through Alembic Therapeutics, the company’s step-down wholly owned subsidiary in the US. The medicine is positioned as a first-line oral antibiotic treatment for uncomplicated urinary tract infections (uUTIs) in women. The company believes the segment offers strong potential due to limited new product launches in the category over the past decade.
Alembic’s India branded formulations business recorded 4% growth and reached Rs 568 crore in quarterly revenue. The company said therapeutic areas including gynaecology, gastrology, ophthalmology, and animal healthcare delivered encouraging performance during the quarter.
The US formulations segment emerged as a key growth driver, posting 11% year-on-year growth to Rs 564 crore. The company launched six products in the US market during the quarter and received four ANDA approvals.
Meanwhile, the API business registered 2% growth to Rs 347 crore during Q4 FY26. On a full-year basis, Alembic reported total revenue of Rs 7,345 crore for FY26, reflecting 10% annual growth over FY25.
